124 related articles for article (PubMed ID: 30259401)
1. Dry Formulations Enhanced Mucoadhesive Properties and Reduced Cold Chain Handing of Influenza Vaccines.
Saengkrit N; Saesoo S; Woramongkolchai N; Sajomsang W; Phunpee S; Dharakul T; Ruktanonchai UR
AAPS PharmSciTech; 2018 Nov; 19(8):3763-3769. PubMed ID: 30259401
[TBL] [Abstract][Full Text] [Related]
2. Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes.
Sawaengsak C; Mori Y; Yamanishi K; Srimanote P; Chaicumpa W; Mitrevej A; Sinchaipanid N
Int J Pharm; 2014 Oct; 473(1-2):113-25. PubMed ID: 24998507
[TBL] [Abstract][Full Text] [Related]
3. Formulation of a dry powder influenza vaccine for nasal delivery.
Garmise RJ; Mar K; Crowder TM; Hwang CR; Ferriter M; Huang J; Mikszta JA; Sullivan VJ; Hickey AJ
AAPS PharmSciTech; 2006 Mar; 7(1):E19. PubMed ID: 16584149
[TBL] [Abstract][Full Text] [Related]
4. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
Garmise RJ; Staats HF; Hickey AJ
AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
[TBL] [Abstract][Full Text] [Related]
5. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants.
Murugappan S; Patil HP; Kanojia G; ter Veer W; Meijerhof T; Frijlink HW; Huckriede A; Hinrichs WL
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):716-25. PubMed ID: 23933147
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine.
Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505
[TBL] [Abstract][Full Text] [Related]
7. Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.
Geeraedts F; Saluja V; ter Veer W; Amorij JP; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
AAPS J; 2010 Jun; 12(2):215-22. PubMed ID: 20195930
[TBL] [Abstract][Full Text] [Related]
8. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation.
Maa YF; Ameri M; Shu C; Payne LG; Chen D
J Pharm Sci; 2004 Jul; 93(7):1912-23. PubMed ID: 15176078
[TBL] [Abstract][Full Text] [Related]
9. Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates.
Scherließ R; Ajmera A; Dennis M; Carroll MW; Altrichter J; Silman NJ; Scholz M; Kemter K; Marriott AC
Vaccine; 2014 Apr; 32(19):2231-40. PubMed ID: 24631078
[TBL] [Abstract][Full Text] [Related]
10. Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying.
Lovalenti PM; Anderl J; Yee L; Nguyen V; Ghavami B; Ohtake S; Saxena A; Voss T; Truong-Le V
Pharm Res; 2016 May; 33(5):1144-60. PubMed ID: 26818839
[TBL] [Abstract][Full Text] [Related]
11. Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.
Flood A; Estrada M; McAdams D; Ji Y; Chen D
PLoS One; 2016; 11(11):e0164692. PubMed ID: 27851765
[TBL] [Abstract][Full Text] [Related]
12. The effect of gamma-irradiation conditions on the immunogenicity of whole-inactivated Influenza A virus vaccine.
David SC; Lau J; Singleton EV; Babb R; Davies J; Hirst TR; McColl SR; Paton JC; Alsharifi M
Vaccine; 2017 Feb; 35(7):1071-1079. PubMed ID: 28109709
[TBL] [Abstract][Full Text] [Related]
13. Development of stable influenza vaccine powder formulations: challenges and possibilities.
Amorij JP; Huckriede A; Wilschut J; Frijlink HW; Hinrichs WL
Pharm Res; 2008 Jun; 25(6):1256-73. PubMed ID: 18338241
[TBL] [Abstract][Full Text] [Related]
14. Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization.
Audouy SA; van der Schaaf G; Hinrichs WL; Frijlink HW; Wilschut J; Huckriede A
Vaccine; 2011 Jun; 29(26):4345-52. PubMed ID: 21514345
[TBL] [Abstract][Full Text] [Related]
15. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
16. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants.
Dehghan S; Tafaghodi M; Bolourieh T; Mazaheri V; Torabi A; Abnous K; Tavassoti Kheiri M
Int J Pharm; 2014 Nov; 475(1-2):1-8. PubMed ID: 25148732
[TBL] [Abstract][Full Text] [Related]
17. A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses.
Rodriguez L; Nogales A; Murcia PR; Parrish CR; Martínez-Sobrido L
Vaccine; 2017 Aug; 35(34):4374-4381. PubMed ID: 28709557
[TBL] [Abstract][Full Text] [Related]
18. Formulation of a dry powder influenza vaccine for nasal delivery.
Garmise RJ; Mar K; Crowder TM; Hwang CR; Ferriter M; Huang J; Mikszta JA; Sullivan VJ; Hickey AJ
AAPS PharmSciTech; 2006 Mar; 7(1):E131-E137. PubMed ID: 28290034
[TBL] [Abstract][Full Text] [Related]
19. A pilot study using a novel pyrotechnically driven prototype applicator for epidermal powder immunization in piglets.
Engert J; Anamur C; Engelke L; Fellner C; Lell P; Henke S; Stadler J; Zöls S; Ritzmann M; Winter G
Int J Pharm; 2018 Jul; 545(1-2):215-228. PubMed ID: 29684561
[TBL] [Abstract][Full Text] [Related]
20. Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration.
Patil HP; Murugappan S; de Vries-Idema J; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
Eur J Pharm Biopharm; 2015 Jun; 93():231-41. PubMed ID: 25896446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
